Тhe role of pentraxin-3 in non-invasive diagnosis of liver fibrosis in patients with non-alcoholic fatty liver disease

Abstract

The aim of the study: to determine the diagnostic value of Pentraxin-3 for the stages of fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Materials and Methods: 40 patients with NAFLD were examined, the mean age was (38.0 ± 4.1) years. The control group was created by 20 healthy individuals. There were no statistically significant differences in gender and age distribution of groups. Transient electrography of the liver was performed using an ultrasound scanner - SIEMENS - ACUSON S 3000. Determination of the level of pentraxin-3 in blood plasma was performed using the enzyme-linked immunosorbent assay using the ELISA kit. Results and Discussion: It was found that the level of Pentraxin-3 depend on the degree of liver fibrosis stage in patients with NAFLD. There was a significant increase of studied biomarker in the case of progression of liver fibrosis stage. Thus, in patients with liver fibrosis stage F0 the level of pentraxin-3 was (254, 35±44, 4) pg/ml, stage F1 – (421, 9±31, 46) pg/ml, and in stage F2 - respectively (430,9±35,86) pg/ml (p<0.05). Conclusion: In patients with NAFLD, the blood plasma’s level of Pentraxin-3 had a significant tendency to increase with the progression of the liver fibrosis stage (p<0.05), which confirms the possibility of using this biomarker in the diagnosis of liver fibrosis stages